Fig. 5

Established metastases are eradicated by A_II in combination with anti-PDL1. A Representative IHC analysis showing CD3⁺ T_AII homing to spontaneous lung metastases in NOG mice. B Quantification of lung metastases. Female hIL15 mice were challenged with an i.v. injection of 10⁶ MDA-MB-231 cells on day 0. On day 7, mice were treated with anti-PDL1 alone (n = 6), A_II alone (n = 6), or combined A_II and anti-PDL1 (n = 6). A_II and anti-PDL1 were administered i.v. and i.p., respectively. 200 µg anti-PDL1 were administered on days 7 and 10 and then once weekly. On day 29, mice were sacrificed, and organs were excised and used for IHC analysis. Mean is shown. C Quantification of the tumor lesions/mm² of the lungs presented in B. mean ± SD is shown. D-E As in B-C, but for the tumor lesions/mm² of liver sections. F Representative IHC analysis of size-matched tumor lesions in liver demonstrating extensive CD3 T_AII cell infiltration in tumors of mice treated with combined A_II and anti-PDL1 vs those treated with anti-PDL1 alone. Statistical difference was determined by the Mann Whitney test B and D *0.05 > P ≥ 0.01, **0.01 > P ≥ 0.001, ***0.001 > P. NS non-significant, a-PDL1 (anti-PDL1). Black and white scale bar 500 and 50 μm, respectively